Previous 10 | Next 10 |
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Methylprednisolone Sodium Succinate for Injection, USP, the generic equival...
Novartis (NVS) has signed an agreement to sell cardiovascular medicine brand Cidmus in India to Dr. Reddy's Laboratories (NYSE:RDY) for $61 million, the Hyderabad-based pharma company disclosed in a regulatory filing on Friday. Cidmus tablets, comprising Valsartan and Sacubitril (patented by ...
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021. Dr. Reddy's will be the exclusive distributor of several of MediCane's medical cannabis products in Germany. Additionally, Dr. Reddy's and MediCane have enter...
Despite possessing solid long-term growth prospects on the back of rising demand from an aging population, many healthcare stocks have been hard hit by the broader market sell-offs over the past couple of months. But given the near-inelastic demand for healthcare solutions and the industry...
BioDelivery Sciences International (BDSI), a specialty pharmaceutical company focused on chronic conditions, announced the U.S. launch of its oral migraine therapy Elyxybtm. Also known as celecoxib oral solution, Elyxybtm is the first and only oral solution approved by the U.S. Food and Drug ...
Novartis India (NIL), a unit of Novartis (NYSE:NVS), signed an exclusive sales and distribution agreement with Dr. Reddy’s Laboratories (NYSE:RDY) for a few of its Established Medicines which includes the pain drug Voveran, the Calcium range and Methergine, used to stop bleeding f...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of its authorized generic version of Par Pharmaceutical’s VASOSTRICT...
Dr. Reddy's Laboratories (RDY -0.8%) is acquiring privately held medical cannabis company Nimbus Health. Dr. Reddy's will acquire Germany-based Nimbus Health, which is a licensed pharmaceutical wholesaler, for an upfront payment plus performance and milestone-based earn-outs over th...
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced that it has entered into a definitive agreement to acquire Nimbus Health GmbH ("Nimbus Health"). Nimbus Health is a p...
Despite supply chain disruptions and labor shortages, the pharma industry is well-positioned to continue growing due to the increasing medical needs of an aging population and advancements in treating chronic diseases. Therefore, amid current market volatility, we believe it could be wise to ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...